Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Get Free Report) has received an average recommendation of “Moderate Buy” from the eight ratings firms that are covering the stock, Marketbeat reports. Four research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $56.33.
AGIO has been the subject of a number of research reports. Royal Bank of Canada boosted their target price on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a research report on Tuesday, December 10th. Scotiabank raised their target price on Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a “sector outperform” rating in a report on Monday, December 9th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Wednesday, December 18th. Raymond James restated an “outperform” rating and set a $51.00 price objective on shares of Agios Pharmaceuticals in a research note on Thursday, October 10th. Finally, StockNews.com raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, November 9th.
Get Our Latest Stock Analysis on Agios Pharmaceuticals
Insider Buying and Selling at Agios Pharmaceuticals
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of AGIO. Sei Investments Co. acquired a new stake in shares of Agios Pharmaceuticals in the 2nd quarter valued at approximately $1,008,000. AQR Capital Management LLC increased its stake in shares of Agios Pharmaceuticals by 196.5% during the 2nd quarter. AQR Capital Management LLC now owns 33,164 shares of the biopharmaceutical company’s stock worth $1,430,000 after purchasing an additional 21,980 shares during the last quarter. The Manufacturers Life Insurance Company grew its holdings in Agios Pharmaceuticals by 54.9% during the second quarter. The Manufacturers Life Insurance Company now owns 137,844 shares of the biopharmaceutical company’s stock worth $5,944,000 after purchasing an additional 48,835 shares during the period. Creative Planning increased its position in Agios Pharmaceuticals by 24.6% during the second quarter. Creative Planning now owns 11,520 shares of the biopharmaceutical company’s stock worth $497,000 after buying an additional 2,276 shares during the last quarter. Finally, SG Americas Securities LLC bought a new stake in Agios Pharmaceuticals in the third quarter valued at approximately $705,000.
Agios Pharmaceuticals Price Performance
Shares of NASDAQ AGIO opened at $33.73 on Thursday. Agios Pharmaceuticals has a 1-year low of $22.23 and a 1-year high of $62.58. The stock has a market capitalization of $1.92 billion, a P/E ratio of 2.97 and a beta of 0.87. The business has a fifty day moving average price of $41.15 and a 200 day moving average price of $44.56.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.
Featured Stories
- Five stocks we like better than Agios Pharmaceuticals
- What Are Earnings Reports?
- How to Short Sell Stocks Like a Pro: Strategies and Tips
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- 3 Steel Stocks Soaring After Tariff Announcements
- When to Sell a Stock for Profit or Loss
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.